Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of January 2022
Filing Date: January 27, 2022
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet incorporating exhibits by reference.
Exhibits Submitted:
- Exhibit 99.1: Appendix 4C and Quarterly Cash Flow Report
Material Changes
The filing text does not contain a narrative discussion of material changes versus the prior comparable period. Financial performance details are contained within the referenced Exhibit 99.1.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, or specific risk factors. The registrant is identified as a "development stage enterprise," implying ongoing research and development activities without commercial revenue generation, though specific details are not in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Appendix 4C and Quarterly Cash Flow Report) for actual cash burn rates and liquidity positions.
- Verify the status of the company's development stage pipeline and any recent clinical milestones not detailed in this cover letter.
- Confirm the incorporation of this report into the listed Registration Statements (Form S-8 and Form F-3) for potential equity issuance implications.
- Check for any subsequent filings that may update the cash flow data referenced in the January 2022 report.